Our rich pipeline of drug programmes has been entirely generated in-house using the Benevolent Platform™, which can work across therapeutic areas.

  • Target ID
  • Chemistry and Lead Optimisation
  • Preclinical
  • Phase I
  • Phase II
BEN-2293 Atopic Dermatitis
BEN-8744 Ulcerative Colitis
BEN-9160 Amyotrophic Lateral Sclerosis
BEN-28010 Glioblastoma Multiforme
Amyotrophic Lateral Sclerosis
Inflammatory Bowel Disease
Antiviral
Oncology
Oncology
Parkinson's disease
Nonalcoholic Steatohepatitis (NASH)
Oncology
Parkinson's disease
Fibrosis
Inflammation
Chronic Kidney Disease
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Chronic Kidney Disease
+10 exploratory programmes

(multiple indications & targets in therapy areas such as Oncology, Immunology, CNS, GI, Metabolic Disorders and Others)

We are actively exploring licensing discussions, and development and commercialisation partnerships for specific assets in our pipeline.

Contact us

What-We-do-Impact-UC-AD.jpg

IMPACT

From target identification to clinical development

Through the combined capabilities of our AI drug discovery Platform, scientific expertise and wet lab facilities, we have rapidly built a substantial portfolio that mixes both potentially best-in-class and first-in-class drug candidates.

BEN-8744: ulcerative colitis